An analysis of the results ofseveral studies confirm previous reports suggesting thatchemotherapy offers little or no survival benefits for youngwomen with estrogen receptor (ER)-positive breast cancers and,if given, it should not be the sole second-phase, or "adjuvant"therapy.
More...